Juvenile Idiopathic Arthritis
📧 Sign up to get email alerts when something new happens for Juvenile Idiopathic Arthritis.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2023-04-14FDA Approved: ADALIMUMAB — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for adalimumab-adaz, a biosimilar to adalimumab, confirming its regulatory approval for use.
-
CLINICAL_TRIALS trial_result · 2023-01-17Clinical Trial Update: Hip Denervation in Juvenile Idiopathic Arthritis With Hip Arthritis [Phase 3]
A Phase 3 trial investigating hip denervation for Juvenile Idiopathic Arthritis with hip arthritis has completed.
-
FDA approval · 2022-12-13FDA Approved: IDACIO — Original Application (Fresenius Kabi USA, LLC)
FDA approved IDACIO (adalimumab-afcf) from Fresenius Kabi USA, LLC as a biosimilar to adalimumab (Humira) under an original Biologics Licens…
-
FDA approval · 2022-11-16FDA Approved: AZULFIDINE EN-TABS — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
The FDA approved a supplemental application for Azulfidine En-Tabs (sulfasalazine) filed by Pfizer Laboratories Div Pfizer Inc.
-
CLINICAL_TRIALS trial_result · 2022-11-14Clinical Trial Update: Extension Study Evaluating Etanercept in 3 Subtypes of Childhood Arthritis [Phase 3]
Phase 3 extension study evaluating etanercept in three subtypes of juvenile arthritis has completed with posted results.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2022-10-07Clinical Trial Update: A Study of Baricitinib in Participants From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis [Phase 3]
A Phase 3 trial evaluating baricitinib in children aged 2 to <18 years with juvenile idiopathic arthritis has completed and posted results.
-
FDA approval · 2022-09-15FDA Approved: CELECOXIB — Supplemental Application (Westminster Pharmaceuticals, LLC)
The FDA approved a supplemental application for a generic celecoxib product from Westminster Pharmaceuticals, expanding access under ANDA210…
-
FDA approval · 2022-07-18FDA Approved: ADALIMUMAB — Supplemental Application (Sandoz Inc)
The FDA approved Sandoz's supplemental application for the adalimumab biosimilar ADALIMUMAB-ADAZ. The approval covers multiple inflammatory …
-
FDA approval · 2022-06-17FDA Approved: ENBREL — Supplemental Application (Immunex Corporation)
The FDA approved a supplemental application for Enbrel (etanercept) from Immunex Corporation, resulting in labeling changes for the product.…
-
FDA approval · 2022-06-07FDA Approved: NAPROXEN — Original Application (Camber Pharmaceuticals, Inc.)
FDA approves Camber's naproxen generic original application for Naproxen. This generic NSAID is approved for relief of pain and inflammation…
-
FDA approval · 2022-05-06FDA Approved: DICLOFENAC SODIUM — Original Application (Apotex Corp.)
FDA approved Apotex Corp's original application for diclofenac sodium tablets, a generic NSAID. This approval enables Apotex to market a gen…
-
FDA approval · 2022-03-09FDA Approved: CELECOXIB — Supplemental Application (Micro Labs Limited)
FDA approved a supplemental application for Celecoxib from Micro Labs Limited under an ANDA.
-
FDA approval · 2022-01-11FDA Approved: CELECOXIB — Supplemental Application (NIVAGEN PHARMACEUTICALS, INC.)
The FDA approved a supplemental application for Celecoxib submitted by NIVAGEN Pharmaceuticals, Inc., for a generic Celecoxib product.
-
FDA approval · 2022-01-07FDA Approved: MELOXICAM — Supplemental Application (Lupin Pharmaceuticals, Inc.)
The FDA approved Lupin Pharmaceuticals' supplemental application for meloxicam, authorizing the generic NSAID product. This marks regulatory…
-
FDA approval · 2022-01-07FDA Approved: MELOXICAM — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for MELOXICAM (meloxicam) from Aurobindo Pharma Limited.
-
FDA approval · 2022-01-05FDA Approved: CELECOXIB — Supplemental Application (Lupin Pharmaceuticals, Inc.)
FDA approved Lupin Pharmaceuticals' supplemental application for a generic celecoxib product (Celecoxib) under ANDA 202240.
-
FDA approval · 2021-12-17FDA Approved: YUSIMRY — Original Application (Coherus BioSciences Inc)
FDA approved YUSIMRY (adalimumab-aqvh) from Coherus BioSciences in an original biologics license application, likely as a biosimilar to adal…
-
FDA approval · 2021-12-14FDA Approved: XELJANZ XR — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved a supplemental application for XELJANZ XR (tofacitinib) submitted by Pfizer Laboratories Div Pfizer Inc. The submission status …
-
FDA approval · 2021-12-02FDA Approved: XELJANZ XR — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved a supplemental application for XELJANZ XR (tofacitinib) from Pfizer Laboratories Div Pfizer Inc. The approval authorizes the ex…
-
FDA approval · 2021-10-15FDA Approved: ADALIMUMAB-ADBM — Supplemental Application (QUALLENT PHARMACEUTICALS HEALTH LLC)
FDA approves a supplemental application for the adalimumab biosimilar ADALIMUMAB-ADBM from Quallent Pharmaceuticals Health LLC. The approval…
-
CLINICAL_TRIALS trial_result · 2021-07-23Clinical Trial Update: Genicular Nerve Block in Juvenile Idiopathic Arthritis [Phase 4]
Phase 4 trial update on genicular nerve block for persistent knee arthritis in Juvenile Idiopathic Arthritis completed.
-
FDA approval · 2021-06-17FDA Approved: INFLECTRA — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approves a supplemental application for INFLECTRA (infliximab-dyyb) from Pfizer Laboratories Div Pfizer Inc, marking FDA action on a bio…
-
FDA approval · 2021-04-28FDA Approved: NAPROXEN — Supplemental Application (Acella Pharmaceuticals, LLC)
The FDA approved a supplemental application for Naproxen filed by Acella Pharmaceuticals, LLC, updating the product's approval status.
-
FDA approval · 2021-04-28FDA Approved: IBUPROFEN — Supplemental Application (Major Pharmaceuticals)
The FDA approved Major Pharmaceuticals' ibuprofen supplemental application, finalizing regulatory changes for this product under an ANDA pro…
-
CLINICAL_TRIALS trial_result · 2021-04-06Clinical Trial Update: Open-Label Extension of the Dose Finding Study (DSC/08/2357/36) in Patients With Poly Juvenile Idiopathic Arthritis [NA]
Open-label extension of a dose-finding study in Juvenile Idiopathic Arthritis has been terminated; results posted in 2021.